It belongs to Wanma Group, a well-known minoxidil hair growth brand in China, and a pharmaceutical industry enterprise integrating research/development/production/sales
Zhejiang Wansheng Pharmaceutical Co., Ltd. (hereinafter referred to as Wansheng Pharmaceutical) is an enterprise with a long history of pharmaceutical production, formerly known as Hangzhou Pharmaceutical Factory, which was acquired by Zhejiang Wanma Group Co., Ltd. in 1997 and acquired by CITIC Industrial Fund in 2014 to complete the reorganization. In July 2015, the company was wholly transferred to Shenyang 3SBio Pharmaceutical Co., Ltd. (HK01530) to start a new journey. She is a high-tech enterprise specializing in drug R&D, production and sales.
Wansheng Pharmaceutical Co., Ltd. firmly establishes the awareness of "the first person responsible for drug quality", abides by national laws, regulations and policies such as the Drug Administration Law, and establishes an all-round, multi-perspective and long-lasting comprehensive quality monitoring system on the basis of production management and quality control in strict accordance with GMP, and successfully passed the 2010 GMP certification in June 2012.
Wansheng Pharmaceutical Co., Ltd. has a wide range of dosage forms, which can produce tablets, capsules, granules (including traditional Chinese medicine), lyophilized powder injections (antineoplastic drugs), biological products, small-volume injections, tinctures, lotions, sprays, ointments, creams, etc. The company has obtained a total of 68 approval numbers, including 25 tablets, 14 lyophilized powder injections, 9 small-volume injections (1 biological product), 4 capsules, 2 granules, 1 tincture, 1 lotion, 2 ointments, 1 spray, and 9 API product approvals.
Wansheng Pharmaceutical's Qingshanhu production base has a total area of 43,495.8 square meters, a construction land of 52.4 acres, and a total construction area of 40,113 square meters. The total design production capacity is 500 million tablets, 25 million hard capsules, 6 million granules, 24 million Chinese medicine granules, 9.6 million lyophilized powder injections, 8 million small-volume injections (tumor lines), 20 million small-volume injections, 32 million biological agents, 5.6 million tinctures, 3.6 million sterile lotions, and 10 million ointments.
Wansheng Pharmaceutical attaches great importance to the investment in the research and development of new products, adopts the "development alliance" model, and has established a scientific research cooperation relationship with more than 30 domestic universities and well-known scientific research institutions, and accelerates the enrichment of the product line through independent research and development, cooperative development, product introduction and other ways.
Wansheng Pharmaceutical has 690 employees, more than 60% of whom have college degree or above. Wansheng Pharmaceutical's sales network covers the whole country, and it has built a clinical sales team of 350 people in dermatology and ophthalmology with a professional promotion model, with annual sales of 330 million.
Wansheng Pharmaceutical actively practices corporate social responsibility, and has been repeatedly commended by the local government in environmental protection, labor relations, and social responsibility construction.
The development strategy of Wansheng Pharmaceutical emphasizes the simultaneous development of Chinese and Western medicines, and gradually develops to the pattern of prescription drugs, basic drugs, and OTC in parallel, with the use of drugs in dermatology and other departments as the dominant field, the use of drugs for diabetic complications as the development field, and the use of tumor drugs as the key focus areas, independently develop and introduce the product group of Wansheng Pharmaceutical, and become a leader in the specialized market segment.
